| Q38566895 | (99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials |
| Q64885825 | 11C-Choline Pharmacokinetics in Recurrent Prostate Cancer. |
| Q37721526 | A Virtual Clinical Trial of FDG-PET Imaging of Breast Cancer: Effect of Variability on Response Assessment. |
| Q42823988 | Acute cytotoxic effects of photoimmunotherapy assessed by 18F-FDG PET. |
| Q35656597 | An anesthetic method compatible with (18)F-FDG-PET studies in mice. |
| Q39506288 | An evaluation of 2-deoxy-2-[18F]fluoro-D-glucose and 3'-deoxy-3'-[18F]-fluorothymidine uptake in human tumor xenograft models |
| Q51348349 | Arterial input function calculation in dynamic contrast-enhanced MRI: an in vivo validation study using co-registered contrast-enhanced ultrasound imaging. |
| Q64085093 | Bias in PET Images of Solid Phantoms Due to CT-Based Attenuation Correction |
| Q26866387 | Biomarkers and molecular probes for cell death imaging and targeted therapeutics |
| Q34998534 | CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab |
| Q41847776 | Calcitriol inhibits hedgehog signaling and induces vitamin d receptor signaling and differentiation in the patched mouse model of embryonal rhabdomyosarcoma |
| Q57494932 | Calibration Software for Quantitative PET/CT Imaging Using Pocket Phantoms |
| Q55465369 | Clinical significance of serum cytokeratin 19 fragment in the prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer |
| Q90229783 | Combined Volumetric and Density Analyses of Contrast-Enhanced CT Imaging to Assess Drug Therapy Response in Gastroenteropancreatic Neuroendocrine Diffuse Liver Metastasis |
| Q52982678 | Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer. |
| Q33758556 | Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imaging |
| Q48047542 | Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients |
| Q34779180 | Current status of methods to assess cancer drug resistance |
| Q34722814 | DOI-based reconstruction algorithms for a compact breast PET scanner. |
| Q45946420 | Development and validation of a prognostic model incorporating texture analysis derived from standardised segmentation of PET in patients with oesophageal cancer. |
| Q26774670 | Development of Companion Diagnostics |
| Q41313977 | Drugs for solid cancer: the productivity crisis prompts a rethink |
| Q42051213 | Dual energy CT for attenuation correction with PET/CT |
| Q47388017 | EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems |
| Q37324886 | Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors |
| Q53580110 | Early 18F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab. |
| Q31107517 | Early Detection of Treatment-Induced Mitotic Arrest Using Temporal Diffusion Magnetic Resonance Spectroscopy. |
| Q41174750 | Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells. |
| Q37558197 | Evaluation of Cross-Calibrated 68Ge/68Ga Phantoms for Assessing PET/CT Measurement Bias in Oncology Imaging for Single- and Multicenter Trials |
| Q40475342 | Evaluation of in vivo quantification accuracy of the Ingenuity-TF PET/MR. |
| Q30645097 | Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures. |
| Q48863637 | Examining changes in [18 F]FDG and [18 F]FLT uptake in U87-MG glioma xenografts as early response biomarkers to treatment with the dual mTOR1/2 inhibitor AZD8055. |
| Q47108153 | Expression Study and Clinical Correlations of MYC and CCAT2 in Breast Cancer Patients. |
| Q90242295 | FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST |
| Q38206772 | FLT PET-CT in evaluation of treatment response. |
| Q52676354 | Feasibility of state of the art PET/CT systems performance harmonisation. |
| Q35971443 | Grand challenges for cancer imaging and diagnosis |
| Q35988082 | How Does the Patient Benefit from Clinical PET? |
| Q36337232 | How to study optimal timing of PET/CT for monitoring of cancer treatment |
| Q50054742 | Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to 177Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor. |
| Q36569572 | Illuminating necrosis: From mechanistic exploration to preclinical application using fluorescence molecular imaging with indocyanine green. |
| Q38853138 | Imaging and therapeutic applications of zinc(ii)-dipicolylamine molecular probes for anionic biomembranes |
| Q37875082 | Imaging assessment of tumor response: past, present and future |
| Q37730090 | Imaging tumour physiology and vasculature to predict and assess response to heat |
| Q46430969 | Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients |
| Q44969342 | Impact of rigid and nonrigid registration on the determination of 18F-FDG PET-based tumour volume and standardized uptake value in patients with lung cancer |
| Q38016943 | Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis |
| Q91617755 | Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma |
| Q57477458 | In Vivo Molecular Imaging Using Low-Boiling-Point Phase-Change Contrast Agents: A Proof of Concept Study |
| Q33798559 | In vivo evaluation of the effects of simultaneous inhibition of GLUT-1 and HIF-1α by antisense oligodeoxynucleotides on the radiosensitivity of laryngeal carcinoma using micro 18F-FDG PET/CT |
| Q33584733 | In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: a pilot study |
| Q33771180 | Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer |
| Q51407617 | Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. |
| Q33838696 | Isolated system towards a successful radiotherapy treatment |
| Q36279415 | Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer |
| Q35144797 | Long non-coding RNA CCAT2 is up-regulated in gastric cancer and associated with poor prognosis |
| Q48265819 | Measuring temporal stability of positron emission tomography standardized uptake value bias using long-lived sources in a multicenter network. |
| Q39238789 | Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver |
| Q26772870 | Molecular Imaging of Biomarkers in Breast Cancer |
| Q34496670 | Molecular imaging in cancer treatment |
| Q36567875 | Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size. |
| Q49694520 | Multicenter survey of PET/CT protocol parameters that affect standardized uptake values |
| Q35113876 | Multimodality imaging of tumor response to doxil |
| Q33572940 | Multimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins |
| Q34762148 | Multiplexed PET probes for imaging breast cancer early response to VEGF₁₂₁/rGel treatment |
| Q36625112 | Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles |
| Q35781966 | Optimization of SPECT-CT Hybrid Imaging Using Iterative Image Reconstruction for Low-Dose CT: A Phantom Study |
| Q33517102 | PET/CT Assessment of Response to Therapy: Tumor Change Measurement, Truth Data, and Error. |
| Q33665109 | PET/CT in Oncology: Current Status and Perspectives |
| Q34940350 | PET/CT without capacity limitations: a Danish experience from a European perspective. |
| Q90260579 | PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues |
| Q64981395 | PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT. |
| Q34774840 | Positron Emission Tomography (PET) in Oncology |
| Q34517660 | Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy |
| Q42679580 | Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial |
| Q38141699 | Predicting tumour response. |
| Q34118056 | Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy |
| Q47399411 | Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. |
| Q37077176 | Prognostic Value of FDG-PET, Based on the Revised Response Criteria, in Patients with Malignant Lymphoma: A Comparison with CT/MRI Evaluations, Based on the International Working Group/Cotswolds Meeting Criteria |
| Q53264976 | QA procedures for multimodality preclinical tumor drug response testing |
| Q35816701 | Quantifying and reducing the effect of calibration error on variability of PET/CT standardized uptake value measurements |
| Q92268734 | Quantitative implications of the updated EARL 2019 PET-CT performance standards |
| Q33857343 | RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline |
| Q37776361 | Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. |
| Q42745746 | Respiratory motion correction for quantitative PET/CT using all detected events with internal-external motion correlation |
| Q38101933 | Role of (18)F-FDG PET-CT in head and neck squamous cell carcinoma |
| Q53222694 | Standard uptake value and metabolic tumor volume of ¹⁸F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. |
| Q59126436 | The 18F-FDG PET/CT response to radiotherapy for patients with spinal metastasis correlated with the clinical outcomes |
| Q33860281 | The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST |
| Q39065889 | The age of reason for FDG PET image-derived indices |
| Q34424266 | The emerging science of quantitative imaging biomarkers terminology and definitions for scientific studies and regulatory submissions. |
| Q56832323 | The potential pitfalls of low-activity protocols in PET/CT imaging |
| Q30393722 | The predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis |
| Q49566963 | The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib. |
| Q30384642 | Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer. |
| Q40011339 | Ultra-low dose CT attenuation correction for PET/CT |
| Q30992320 | Ultra-low dose CT attenuation correction for PET/CT: analysis of sparse view data acquisition and reconstruction algorithms |
| Q95360908 | Usefulness of positron emission mammography in the evaluation of response to neoadjuvant chemotherapy in patients with breast cancer |
| Q36626050 | Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings |
| Q34645445 | [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice |
| Q86898697 | [Rational imaging of metastasized tumor diseases] |
| Q64085087 | ePAD: An Image Annotation and Analysis Platform for Quantitative Imaging |